Sponsor Directory

AstraZeneca clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1904

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Interventions: OLAPARIB; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 35
States / cities: Anchorage, Alaska • La Jolla, California • Los Angeles, California + 29 more

Conditions: Myocardial Infarction (MI)
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: Up to 130 Years
Enrollment: 7,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Bethesda, Maryland • Waltham, Massachusetts

Conditions: Chronic Lymphocytic Leukemia, CLL/SLL
Interventions: Acalabrutinib; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myeloid Leukaemia
Interventions: AZD2811, Azacitidine, Venetoclax; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 10
States / cities: Denver, Colorado • Sarasota, Florida • Detroit, Michigan + 7 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Gefitinib, MEDI4736; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 3
States / cities: Tampa, Florida • Houston, Texas • Seattle, Washington

Conditions: Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Entinostat, Olaparib; Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Kansas City, Kansas • Nashville, Tennessee

Conditions: Renal Impairment
Interventions: AZD9977; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 6
States / cities: Northridge, California • DeLand, Florida • Hialeah, Florida + 3 more

Conditions: Atopic Dermatitis
Interventions: Tezepelumab, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 16
States / cities: Fountain Valley, California • Santa Monica, California • Alpharetta, Georgia + 12 more

Conditions: Recurrent Platinum Resistant Ovarian Cancer
Interventions: cediranib and olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 25
States / cities: Mobile, Alabama • Anchorage, Alaska • Downey, California + 21 more

Conditions: Lung Cancer, Non-small Cell Lung Cancer, PD-L1 Gene Mutation, KRAS Activating Mutation
Interventions: Durvalumab, Carboplatin, Pemetrexed; Drug
Lead sponsor: Shirish M Gadgeel; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Type 2 Diabetes
Interventions: Dapagliflozin, Dapagliflozin placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 10 Years to 24 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 15
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Gainesville, Florida + 11 more

Conditions: Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive, Lung Diseases, Respiratory Hypersensitivity, Hypersensitivity, Immediate, Hypersensitivity, Immune System Diseases
Interventions: Tezepelumab, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 5
States / cities: Denver, Colorado • New Haven, Connecticut • Boston, Massachusetts + 2 more

About this AstraZeneca sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AstraZeneca is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AstraZeneca trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AstraZeneca clinical trials

Filter and sort this sponsor

Live official records

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical Practice

Early Intervention With Acalabrutinib in Patients With High Risk CLL

Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer

Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients

Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years

Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)

About this AstraZeneca sponsor directory page